HC Wainwright & Co. Maintains Buy on Calumet, Raises Price Target to $60

HC Wainwright & Co. analyst Amit Dayal has maintained a Buy rating on Calumet (NASDAQ: CLMT) and increased the price target from $33 to $60. This adjustment reflects a positive outlook for the company's performance.